Covira is a biotech company, a spinout from The University of Chicago (Sept 2018), developing drugs that work by modulating the biological activity of the gut microbiome to prevent diseases. 

This microbiome-focused company is based on the work of Dr. John Alverdy, MD, a world authority on the molecular basis of post-surgical infections. Covira’s platform technology generated a lead asset (CS-0003) that modulates bacterial virulence and restores microbial communities to prevent post-surgical infection. Covira’s approach is transformative to the field. In October 2022, after a 7-month competitive process with more than 4,000 early-stage US companies, Covira was named 1 of 16 Most Fundable Companies, Pepperdine Graziadio Business School Announces the 2022 List of Most Fundable Companies.